ArticleCancer research2019
Chromosome 12p Amplification in Triple-Negative/
Open access · greenAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions.International journal of molecular sciences · 2025Review
- USP51/GRP78/ABCB1 axis confers chemoresistance through decreasing doxorubicin accumulation in triple-negative breast cancer cells.Acta pharmaceutica Sinica. B · 2025Article
- Pan-Cancer Single-Nucleus Total RNA Sequencing Using snHH-Seq.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer.Journal of the National Cancer Institute · 2023Article
- The progress in our understanding of CIN in breast cancer research.Frontiers in oncology · 2023Review
- Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy-a case report.Annals of translational medicine · 2022Article
- Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel <em>via</em> targeting miR-200b-3p/Bcl-2 axis.European journal of histochemistry : EJH · 2022Article
- Review
- Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.Scientific reports · 2021Article
- The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.Molecular cancer research : MCR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 10 institutions in 3 countries.
Jorge Gómez-MiragayaCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0003-1801-4681
Ander Díaz-NavarroDepartamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), CIBERONC, Universidad de Oviedo, Oviedo, Spain.ORCID 0000-0001-6808-4800
Raul TondaCNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.ORCID 0000-0001-7893-2404
Sergi BeltranCNAG-CRG, Centre for Genomic Regulation (CRG), Institute of Science and Technology (BIST), Centre for Genomic Analysis (CNAG), Barcelona, Spain.
Luis PalomeroBreast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
Marta PalafoxCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
Lacey E DobroleckiDepartments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Chen HuangDepartments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Suhas VasaikarDepartments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Bing ZhangDepartments of Molecular and Human Genetics, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-8676-2425
Gerburg M WulfDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Alejandro Collado-SoleCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.
Eva M TrinidadCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0001-6090-5205
Purificación MuñozCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID 0000-0002-3751-2099
Laia ParéTranslational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Aleix PratTranslational Genomics and Targeted Therapeutics in Solid Tumors, Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
Alejandra BrunaCancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Carlos CaldasCancer Research UK Cancer Centre, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Joaquín ArribasPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-0504-0664
María Teresa Soler-MonsoPathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
Anna PetitPathology Department, University Hospital of Bellvitge, IDIBELL, Barcelona, Spain.
Judith BalmañaPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Cristina CruzPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0002-6474-7504
Violeta SerraPreclinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.ORCID 0000-0001-6620-1065
Miguel Angel PujanaBreast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0003-3222-4044
Michael T LewisDepartments of Molecular and Cellular Biology and Radiology, The Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
Xose S PuenteDepartamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), CIBERONC, Universidad de Oviedo, Oviedo, Spain.ORCID 0000-0001-9525-1483
Eva González-SuárezCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Avinguda de la Gran Via, 199-203, L'Hospitalet de Llobregat, Barcelona, Spain. egsuarez@idibell.cat.
Institut d'Investigació Biomédica de Bellvitge · ESBaylor College of Medicine · USVall d'Hebron Institut de Recerca · ESBreast Cancer Research Foundation · USCancer Research UK Cambridge Center · GBInstitut Català d'Oncologia · ESUniversidad de Oviedo · ESUniversitat Pompeu Fabra · ESBeth Israel Deaconess Medical Center · USInstitució Catalana de Recerca i Estudis Avançats · ES
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5MTolinapant efficacy in a subset of triple negative breast cancersU54CA224076 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Alana L. Welm · 2017 to 2026
$13.5MOptimization of PI3K-inhibitors to augment the efficacy of microtubule-disrupting chemotherapyR01CA226776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WULF, GERBURG M · 2018 to 2022
$2.1MCancer Research UK 16942European Research Council 682935NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS R01 CA226776NCI NIH HHS U54 CA224076
Abstract
Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with
Indexed as
Chromosomes, Human, Pair 12AnimalsBRCA1 ProteinCarboplatinCell Line, TumorDocetaxelDrug Resistance, NeoplasmExomeFemaleHumansMiceMutationTreatment OutcomeTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysBRCA1 ProteinBRCA1 protein, humanCarboplatinDocetaxel
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.